THE NUMBERS
COSTS UP. PRICES DOWN. SOMETHING'S GOTTA GIVE.
For the period 2015-2025
R&D Cost Source: Drug Channels Institute / SSR Health
Net Price Source: Tufts Center for the Study of Drug Development
the problem
DEMAND IS THERE.
ACCESS ISN’T.
Traditional Channels
Access is restricted
Prior authorization and step therapies delay or prevent treatment
Rebate structures prioritize formulary economics over patients
Employers lack control over cost-sharing and access design
Cash Pay Maze
Access is unaffordable
Millions of clinically eligible patients lack coverage
Prices out of reach for most buyers
No aggregation or coordination of demand
The andel model
THE ACCESS CHANNEL THE MARKET IS MISSING
We connect employer funding with manufacturer pricing.
Additive to existing channels—not a replacement
why andel works for pharma
WE DRIVE INCREMENTAL UTILIZATION
Incremental, not cannibalistic
Reaches patients outside traditional channels
Predictable demand
Aggregated employer base creates stable volume
Faster time to therapy
Removes administrative delays to initiation
Stronger adherence
Lower cost burden improves persistence
Full channel visibility
Direct insight into demand and utilization
Therapeutic Areas
Immunology
Autoimmune diseases
Dermatology
Chronic dermatologic conditions
Oncology
Cancer therapies and supportive care
Neurology
Epilepsy and migraine
Fertility
Assisted reproduction
Approaching LOE
Lifestyle and price optimization
Cardiometabolic
Obesity, diabetes, lipids
How Andel fits
INCREMENTAL TO EXISTING CHANNELS
Channel
ANDEL ADDS
Structured, employer-funded demand
Copay Programs
Works outside traditional coverage
THE SHIFT TO DIRECT-TO-EMPLOYER IS UNDERWAY
Millions of covered lives seeking alternatives
High-spend categories being carved out
Pressure to expand access without raising premiums